Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: Results from the phase II DUNE trial (GETNE 1601)

被引：1
|
作者：
Hernando, J. [1 ]
Manzano, J. L. [2 ]
Teule, A. [3 ]
Lopez, C. [4 ]
Garcia-Carbonero, R. [5 ]
Benavent Vinuales, M. [6 ]
Custodio, A. [7 ]
Cubillo, A. [8 ]
Alonso, V. [9 ]
Alonso-Gordoa, T. [10 ]
Carmona-Bayonas, A. [11 ]
Crespo, G. [12 ]
Blanco, M. [13 ]
Jimenez-Fonseca, P. [14 ]
Viudez, A. [15 ]
La Casta, A. [16 ]
Sevilla, I. [17 ]
Llanos, M. [18 ]
Segura, A. [19 ]
Capdevila, J. [1 ]
机构：
[1] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain
[2] Inst Catala Oncol ICO Badalona, Hosp Germans Trias i Pujol, Dept Med Oncol, Badalona, Spain
[3] Inst Catala Oncol ICO IDIBELL, Med Oncol Dept, Lhospitalet De Llobregat, Spain
[4] Hosp Univ Marques Valdecilla, IDIVAL, Med Oncol Dept, Santander, Spain
[5] Hosp Univ 12 Octubre, Imas12, UCM CNIO, Med Oncol Dept, Madrid, Spain
[6] Univ Hosp Virgen Rocio, Inst Biomed Sevilla IBIS, Med Oncol Dept, Seville, Spain
[7] Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain
[8] Hosp Univ HM Sanchinarro, Med Oncol Dept, Madrid, Spain
[9] Inst Invest Sanitaria Aragon IISA, Hosp Univ Miguel Servet, Dept Med Oncol, Zaragoza, Spain
[10] Hosp Univ Ramon & Cajal, Med Oncol, Madrid, Spain
[11] Hosp Univ Morales Meseguer, UMU, IMIB, Hematol & Med Oncol Dept, Murcia, Spain
[12] Complejo Asistencial Univ Burgos, Med Oncol Dept, Burgos, Spain
[13] Hosp Univ Gregorio Maranon, Med Oncol Dept, Madrid, Spain
[14] Hosp Univ Cent Asturias, ISPA, Med Oncol Dept, Oviedo, Spain
[15] Complejo Hosp Navarra, Medica Oncol Dept, Pamplona, Spain
[16] Hosp Univ Donostia, Dept Med Oncol, San Sebastian, Spain
[17] Hosp Univ Reg & Virgen Victoria Malaga, Inst Invest Biomed Malaga IBIMA, Invest Clin & Traslac Canc, Med Oncol Dept, Malaga, Spain
[18] Hosp Univ Canarias, Med Oncol Dept, San Cristobal la Laguna, Spain
[19] Hosp Univ Fe, Med Oncol Dept, Valencia, Spain
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.181
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1099MO
引用
收藏
页码：S909 / S910
页数：2
相关论文
共 31 条
  • [21] Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial
    Giannatempo, P.
    Bottiglieri, A.
    Guadalupi, V.
    Marandino, L.
    Raggi, D.
    Stellato, M.
    Rametta, A.
    Baciarello, G.
    Sepe, P.
    Claps, M.
    Buti, S.
    Pipitone, S.
    Iacovelli, R.
    Calareso, G.
    Alessi, A.
    Cattaneo, L.
    Verzoni, E.
    Ortega, C.
    Procopio, G.
    Necchi, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1205 - S1205
  • [22] Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial
    Kimbung, Siker
    Markholm, Ida
    Bjohle, Judith
    Lekberg, Tobias
    von Wachenfeldt, Anna
    Azavedo, Edward
    Saracco, Ariel
    Hellstrom, Mats
    Veerla, Srinivas
    Paquet, Eric
    Bendahl, Par-Ola
    Ferno, Marten
    Bergh, Jonas
    Loman, Niklas
    Hatschek, Thomas
    Hedenfalk, Ingrid
    INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (03) : 618 - 628
  • [23] A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress)
    Kyoichi Kaira
    Atsuto Mouri
    Shingo Kato
    Kenichi Yoshimura
    Hiroshi Kagamu
    Kunihiko Kobayashi
    BMC Cancer, 20
  • [24] The efficacy and safety profile of anlotinib with etoposide plus cisplatin/carboplatin in treatment-naive extensive-stage small cell lung cancer(SCLC) patients: Results from a phase II single-arm trial.
    Deng, Pengbo
    Yang, Huaping
    Chen, Cen
    Hu, Chengping
    Cao, Liming
    Gu, Qihua
    An, Jian
    Li, Bin
    Tang, Yongjun
    Meng, Jie
    Feng, Juntao
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Safety and efficacy of durvalumab plus carboplatin and etoposide for patients with previously untreated extensive-stage small-cell lung cancer (ES-SCLC) with a poor performance status: The results from phase II single-arm study (NEJ045A study).
    Saida, Yu
    Asao, Tetsuhiko
    Watanabe, Satoshi
    Kisohara, Akira
    Kishi, Kazuma
    Morita, Ryo
    Nakagawa, Taku
    Tsukita, Yoko
    Furuya, Naoki
    Miyawaki, Taichi
    Ishikawa, Nobuhisa
    Yamada, Tadaaki
    Tanaka, Takahiro
    Morita, Satoshi
    Kikuchi, Toshiaki
    Maemondo, Makoto
    Kobayashi, Kunihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74years old and patients with PS 0 or 1 from 75years: NEJ039A (trial in progress)
    Kaira, Kyoichi
    Mouri, Atsuto
    Kato, Shingo
    Yoshimura, Kenichi
    Kagamu, Hiroshi
    Kobayashi, Kunihiko
    BMC CANCER, 2020, 20 (01)
  • [27] PHASE II TRIAL OF THE AKT INHIBITOR MK-2206 PLUS ERLOTINIB (ERL) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED AFTER PRIOR BENEFIT (RESPONSE OR STABLE DISEASE) FROM ERL: INTERIM RESULTS FROM PHII-108 (NCI 8698), A CALIFORNIA CANCER CONSORTIUM TRIAL
    Lara, Primo
    Longmate, Jeffrey
    Mack, Philip C.
    Kelly, Karen
    Li, Tianhong
    Koczywas, Mariana
    Reckamp, Karen
    Gandara, David
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : S105 - S106
  • [28] Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
    Wang, Q. M.
    Wu, Y.
    Wang, Q.
    Ma, S.
    Lu, H.
    Liu, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1674 - S1674
  • [29] Interim results from a phase I/II study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN)
    Choudhury, N.
    Jain, P.
    Dowlati, A.
    Thompson, J.
    Johnson, M. L.
    Mamdani, H.
    Sanborn, R. E.
    Schenk, E. L.
    Aggarwal, R.
    Sankar, K.
    Walker, L. N.
    Anand, B.
    Beltran, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S486 - S486
  • [30] Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Schiller, J. H.
    Akerley, W. L.
    Brugger, W.
    Ferrari, D.
    Garmey, E. G.
    Gerber, D. E.
    Orlov, S. V.
    Ramlau, R.
    Von Pawel, J.
    Sequist, L. V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
1234